Regulatory T-cells (Tregs) Therapies Market Key Players Analysis - Abata Therapeutics (US), Cellenkos Inc (US), Coya Therapeutics (US), Roche (Switzerland), Caladrius Biosciences (US).

Regulatory T-cells (Tregs) Therapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Regulatory T-cells (Tregs) therapies Market Trends, Clinical Trial/Pipeline Analysis, Funding Analysis, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the most recent research report, the global regulatory T-cells (Tregs) therapeutics market is estimated to reach $1,138.6 million by 2030, growing at a CAGR of 52.8% from 2025 to 2030. There is currently no approved marketed product for Regulatory T-cells (Tregs) therapies in the global market, with the first product likely to be launched in 2024-2025.

Get Free Access to Demo Report, Excel Pivot and ToC :https://www.insightaceanalytic.com/request-sample/1200

Regulatory T cells (Tregs) are a group of immune cells that can decrease the immune response and contribute to homeostasis and self-tolerance. Many preclinical investigations have indicated that Tregs can suppress T cell proliferation, cytokine generation, and play an important role in modulating autoimmune reactions. The regulatory T-cells (Tregs) therapies market is growing due to a variety of factors, including the high prevalence of autoimmune and inflammatory diseases, the growing geriatric population, increased public awareness of healthcare and wellness, the emergence of new techniques such as next-generation T-cell immunotherapy, rising healthcare expenditure, and increased R&D investments to innovate adoptive Treg therapies.
The current COVID-19 pandemic has prompted researchers to focus more on understanding the novel applications of T-cell treatments in viral infection research. In December 2020, Miltenyi Biotec (Germany) introduced new kits for efficiently stimulating and analyzing SARS-CoV-2-reactive T cells. The kits, designed for quick detection in PBMC samples following stimulation with the SARS-CoV-2 PepTivator Peptide Pools published earlier this year, represent decades of experience in designing solutions for virus-specific T cell research. As a result, increased R&D activities are expected to open up new potential for the regulatory T-cell (Treg) therapeutics market in the coming years.
However, the difficult manufacture of regulatory T-cell immunotherapies, the high cost of Treg therapies, and the limited adverse effects of these therapies are expected to impede market acceptance in the coming years.
The Asia Pacific region is expected to grow significantly during the forecast period (2025-2030) as a result of the government's increased research funding and investments, rising chronic disease prevalence, and rapid adoption of advanced drug development and therapy techniques.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Major market players operating in the regulatory T-cells (Tregs) therapies market include Abata Therapeutics (US), Cellenkos Inc (US), Coya Therapeutics (US), Roche (Switzerland), Caladrius Biosciences (US), Sonoma Biotherapeutics (US), Nektar Therapeutics (US), Eli Lilly and Company (US), REGiMMUNE (US), Miltenyi Biotec (Germany), TeraImmune (US), TRACT Therapeutics (US), VT Bio (South Korea), Amgen (US), Sangamo Therapeutics (TxCell) (US), Pfizer Inc. (US), PolTREG S.A.. (Poland), Parvus Therapeutics (Canada), ILTOO Pharma (France), Philogen S.p.A. (Italy), Celgene (US), AHEAD THERAPEUTICS S.L. (Spain) among others.

Key developments in the market:
• In July 2021, the U.S. FDA granted Orphan Drug Designation to Coya Therapeutics's ALS001, an autologous, expanded Treg cell therapy in development to treat amyotrophic lateral sclerosis (ALS).
• In February 2021, Coya Therapeutics, Inc. (US) merged with Nicoya Health, Inc. It raised $10 million in Series A financing from institutional and accredited investors to advance the pipeline of regulatory T cell therapeutics optimized for neurodegeneration and autoimmune diseases.
• In May 2021, Nektar Therapeutics (US) announced the first publication of NKTR-358, a first-in-class composition of stable PEG conjugates of native IL-2 designed to selectively stimulate expansion and selective function of T regulatory cells, in the journal of translational autoimmunity. NKTR-358 is in the development for the treatment of a range of autoimmune and inflammatory disorders.
• In November 2020, the U.S FDA approved TRACT Therapeutics's investigational drug candidate, TRK-001, for its potential to reduce organ rejection following solid organ transplantation.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1200

Market Segments
Regulatory T-cells (Tregs) therapies Market, by Target Indication, 2025-2030 (Valu US$ Mn)
• Crohn Disease
• Bipolar Disorder
• Allergic Rhinoconjunctivitis
• COVID 19
• Diabetes Mellitus
• Systemic Lupus Erythematosus
• Alzheimer Disease
• Graft Vs Host Disease
Regulatory T-cells (Tregs) therapies Market, by Products, 2025-2030 (Valu US$ Mn)
• Tregs
• Interleukin 2
• Monoclonal Antibodies
• Small Molecules
• Other Products
Regulatory T-cells (Tregs) therapies Market, by Region, 2025-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Regulatory T-cells (Tregs) therapies Market, by Country, 2025-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Regulatory T-cells (Tregs) therapies Market, by Country, 2025-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Regulatory T-cells (Tregs) therapies Market, by Country, 2025-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Regulatory T-cells (Tregs) therapies Market, by Country, 2025-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
The Middle East & Africa Regulatory T-cells (Tregs) therapies Market, by Country, 2025-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of the Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1200

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.